Kent and Medway NHS and Social Care Partnership Trust.
AKFA University Medical School, Uzbekistan.
Age Ageing. 2022 Aug 2;51(8). doi: 10.1093/ageing/afac196.
many medications possess anticholinergic activity. Their use is associated with a number of serious adverse effects including cognitive effects. The cumulative anticholinergic effect of medications as assessed by tools such as the anticholinergic burden scale (AchB) can identify people particularly at risk of anticholinergic side-effects. Currently, >20 tools are available for clinicians to use, but there is no consensus on the most appropriate tool.
a newly created online tool-International Anticholinergic Cognitive Burden Tool (IACT)-based on natural language processing and chemical structure analysis, was developed and made available for clinicians to test its functions. We carried out a survey (between 8th of February and 31st of March 2021) to assess the overall need for an assessment tool as well as the usability of the IACT.
a total of 110 responses were received from different countries and practitioners' groups. The majority of the participants (86.11%) stated they would use a tool for AchB assessment if available and when they were asked to rate the IACT against other tools, amongst 34 responders, 20.59% rated it better and 8.82% rated it significantly better, 44.12% rated it neither better, nor worse, 14.71% rated it worse and 11.76% somewhat worse.
there is a need for an anticholinergic burden calculator to assess the anticholinergicity of medications. Tools such as the IACT potentially could meet this demand due to its ability to assign scores to current and new medications appearing on the market based both on their chemical structure and reported adverse pharmacological effects.
许多药物具有抗胆碱能活性。它们的使用与许多严重的不良反应有关,包括认知效应。药物的累积抗胆碱能效应可以通过抗胆碱能负担量表(AchB)等工具来评估,从而确定特别容易发生抗胆碱能副作用的人群。目前,有超过 20 种工具可供临床医生使用,但对于最适合的工具尚无共识。
我们开发了一种新的在线工具——国际抗胆碱能认知负担工具(IACT),它基于自然语言处理和化学结构分析,供临床医生测试其功能。我们进行了一项调查(2021 年 2 月 8 日至 3 月 31 日),以评估评估工具的总体需求以及 IACT 的可用性。
我们收到了来自不同国家和医生群体的 110 份回复。大多数参与者(86.11%)表示,如果有可用的 AchB 评估工具,他们将使用该工具,当被要求对 IACT 与其他工具进行评分时,在 34 名回答者中,20.59%认为它更好,8.82%认为它明显更好,44.12%认为它既不差也不好,14.71%认为它更差,11.76%认为它稍差。
需要有一种抗胆碱能负担计算器来评估药物的抗胆碱能性。像 IACT 这样的工具由于其能够根据药物的化学结构和报告的不良药理作用,为市场上出现的现有和新药物分配分数,因此可能满足这一需求。